Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer
Findings Presented at 89 th Annual Meeting of the American Thyroid Association SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data that advance understanding of the frequency, positive predictive value and co-occurrence of genomic
View HTML
Toggle Summary Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association
Findings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data advancing the understanding of
View HTML
Toggle Summary Veracyte Announces Third Quarter 2019 Financial Results and Business Progress
Revenue Grew 32% to $31.0 Million Genomic Test Volume Grew 24% to 9,941 Company Presents Preliminary Data for First-Ever Noninvasive Nasal Swab Test for Lung Cancer Early Detection Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct.
View HTML
Toggle Summary Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis
Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021 Conference call and webcast today at 5:00 p.m. ET to review third quarter 2019 Financial results and the new nasal swab test data SOUTH SAN FRANCISCO --(BUSINESS WIRE)--Oct.
View HTML
Toggle Summary Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive
Data Being Presented at CHEST Annual Meeting 2019 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 21, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced data demonstrating the clinical validity of its next-generation Percepta ® Genomic Sequencing Classifier (GSC) and the clinical utility of
View HTML
Toggle Summary Veracyte Announces New Data Demonstrating That Envisia Genomic Classifier Improves IPF Diagnosis
Results From Three Studies Presented at CHEST 2019 Suggest Test Increases Physicians’ Confidence in Diagnosis and Can Reduce the Need for Invasive, Risky Procedures SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 21, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced that data from three studies
View HTML
Toggle Summary Veracyte to Release Third Quarter 2019 Financial Results and Business Progress on October 22, 2019
  SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 8, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the third quarter 2019 and business progress after the close of market on Tuesday, October 22, 2019 .
View HTML
Toggle Summary Veracyte to Announce New Clinical Data for First Noninvasive Nasal Swab Test to Target Early Lung Cancer Detection at CHEST Annual Meeting 2019
  Five Studies Reinforcing Clinical Performance and Utility of Company’s Marketed Genomic Tests in Lung Cancer and IPF Diagnosis Will Also Be Presented     SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 7, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced that preliminary clinical data for
View HTML
Toggle Summary Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas
RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 11, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data demonstrating the clinical and analytical validity of its
View HTML
Toggle Summary Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer
Data support use of Afirma Xpression Atlas to inform surgery and treatment decisions at time of diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 3, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data that further define the genomic landscape around thyroid
View HTML